Urgent need for new AMD drugs

Article

The decline in quality of life (Qol) and the increased need for daily living assistance in patients with wet age-related macular degeneration (AMD) substantiates the need for new treatments that can halt disease progression, according to a multi-country study published in the September issue of Archives of Ophthalmology.

The decline in quality of life (Qol) and the increased need for daily living assistance in patients with wet age-related macular degeneration (AMD) substantiates the need for new treatments that can halt disease progression, according to a multi-country study published in the September issue of Archives of Ophthalmology.

Researchers from France, Canada, England, Germany, Spain and the US conducted a cross-sectional study of 401 patients with bilateral wet AMD and 471 elderly controls without AMD. All subjects completed a telephone survey, including the National Eye Institute 25-item Visual Function Questionnaire, the EuroQol instrument, the Hospital Anxiety and Depression Scale. Subjects were also asked about any history of falls, fractures and healthcare resource utilisation.

The patients reported 45% worse vision-related functioning, 13% worse overall wellbeing, 30% more anxiety and 42% more depression than controls. Those with AMD reported twice as many falls (subject group: 16% vs controls: 8%) and a quadrupled need for assistance with daily activities (subject group: 29% vs controls: 7%) than controls.

The researchers concluded that the dramatically reduced quality of life and the increased reliance on health resources that is seen in patients with wet AMD substantiate the need for new drugs that halt disease progression and prevent blindness.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.